Logo

EU Clears Third Wave's HPV Test; Sales to Start after New Year

Dec 06, 2007
This article has been updated.
 
NEW YORK (GenomeWeb News) - Third Wave Technologies’ HPV test has received CE Marking from European regulators, the company said yesterday.
 
The clearance from the European Union gives the company the green light to sell the test, which detects 14 high-risk types of HPV and is used in screening for cervical cancer, in EU member nations and in other nations that recognize the CE mark.
 
The company said it expects to market the test in Europe in January 2008.
 
Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.